BiolineRx
Oncology Therapeutic Pharmaceutical Candidates
StartupBiolineRx is a Modi'in-Maccabim-Re'ut-based startup in the Health Tech & Life Sciences sector, established in 2003. Oncology Therapeutic Pharmaceutical Candidates. The company has raised a total of $208.64M across 18 funding rounds, currently at the Public stage. Key investors include Highbridge Capital Management, Kreos Capital, Undisclosed Investor(s), among 10 total investors. The company has 51-200 employees. Core technologies: Biologicals.
With $208.64M in total funding, BiolineRx is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees51-200
- HQModi'in-Maccabim-Re'ut
- DistrictCenter District
- Last Round$10M
- Highbridge Capital ManagementLead
- Kreos Capital
- Undisclosed Investor(s)
10 investors total
123 articles covered by sources including finance.yahoo.com,
www.prnewswire.com,
en.globes.co.il,
www.blackhillsfox.com,
www.directorstalkinterviews.com.
What does BiolineRx do?
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The company's pipeline currently consists of BL-8040, a platform for multiple cancer and hematological indications; and AGI-134, a synthetic immunotherapy in development for solid tumors. The BioLineRx pipeline is generated by systematically identifying, validating, and in-licensing therapeutic candidates with advantages over current therapies or that address unmet medical needs. BioLineRx also works with Novartis on the codevelopment of selected Israel-sourced novel drug candidates and has recently signed a collaboration agreement with MSD (known as Merck in the United States and Canada) to run a phase-2a study in pancreatic cancer using a combination of BL-8040 and Merck's Keytruda. BioLineRx has received the FDA biological product designation for its novel cancer immunotherapy candidate AGI-134. In January 2020, the company announced that the European Commission had granted orphan drug designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer.
How much funding has BiolineRx raised?
BiolineRx has raised $208.64M in total funding across 18 rounds. The company is currently at the Public stage. Key investors include Highbridge Capital Management, Kreos Capital, Undisclosed Investor(s).
What sector is BiolineRx in?
BiolineRx operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is BiolineRx located?
BiolineRx is based in HaMa'ayan Street 2, Modi'in-Maccabim-Re'ut, Israel, Center District.